Capmatinib: all 44 studies that test it

Page 1 of 1. Open to participants first (4), then studies with results posted, then the rest; newest registration first within each.

• DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET DysregulationsRecruitingNCT06988475Phase 2/3
• Neoadjuvant and Adjuvant Targeted Treatment in NSCLC With BRAF V600 or MET Exon 14 MutationsNot yet recruitingNCT06054191Phase 2
• DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening ProtocolRecruitingNCT05722886Phase 2/3
• European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory TumorsRecruitingNCT02813135Phase 1/2
• Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis TestTerminatedNCT05243641Phase 1/2Results posted
• Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC.CompletedNCT05110196Phase 4Results posted
• Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLCTerminatedNCT04926831Phase 2Results posted
• Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line TherapyTerminatedNCT04816214Phase 3Results posted
• Study of Capmatinib in Chinese Adult Patients With Advanced Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping MutationCompletedNCT04677595Phase 2Results posted
• Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping MutationTerminatedNCT04427072Phase 3Results posted
• Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50%TerminatedNCT04139317Phase 2Results posted
• Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung CancerCompletedNCT03647488Phase 2Results posted
• Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCCCompletedNCT02795429Phase 1/2Results posted
• A Study of Capmatinib (INC280) in NSCLC Patients With MET Exon 14 Alterations Who Have Received Prior MET InhibitorCompletedNCT02750215Phase 2Results posted
• Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV MelanomaTerminatedNCT02587650Phase 2Results posted
• Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)CompletedNCT02414139Phase 2Results posted
• Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer.TerminatedNCT02335944Phase 1/2Results posted
• Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung CancerTerminatedNCT02323126Phase 2Results posted
• A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung CancerCompletedNCT02276027Phase 2Results posted
• LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF MelanomaCompletedNCT02159066Phase 2Results posted
• A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell CancerCompletedNCT02019693Phase 2Results posted
• Study Efficacy and Safety of INC280 in Patients With Advanced Hepatocellular Carcinoma.TerminatedNCT01737827Phase 2Results posted
• A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi TreatmentCompletedNCT01610336Phase 2Results posted
• Central Nervous System Efficacy of Capmatinib in NSCLC With Brain Metastases With cfDNA Positive MET AlterationsWithdrawnNCT05567055Phase 2
• A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung CancerActive, not recruitingNCT05488314Phase 1/2
• Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping MutationTerminatedNCT05435846Phase 1
• Combination of Capmatinib + Spartalizumab in Advanced Oesogastric AdenocarcinomaSuspendedNCT05135845Phase 2
• A Phase II, Open-Label, Multicenter Study of Capmatinib in Subjects With MET Exon 14 Skipping Mutation Positive, Advanced, NSCLC With Brain MetastasesWithdrawnNCT04460729Phase 2
• Molecular Profiling of Advanced Soft-tissue SarcomasCompletedNCT03784014Phase 3
• Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).TerminatedNCT03742349Phase 1
• Capmatinib in Patients With Non-small Cell Lung Cancer Harboring cMET exon14 Skipping MutationStatus unknownNCT03693339Phase 2
• Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC)WithdrawnNCT03240393Phase 2
• A Dose Escalation Study to Assess PK, Safety and Tolerability of INC280 When Taken With Food in cMET Dysregulated Advanced Solid Tumors.CompletedNCT02925104Phase 1
• A Drug-drug Interaction (DDI) Study to Assess the Effect of INC280 on the Pharmacokinetics of Digoxin and Rosuvastatin in Patients With cMET-dysregulated Advanced Solid TumorsCompletedNCT02626234Phase 1
• A DDI Study to Assess the Effect of INC280 on the PK of Midazolam and Caffeine in Patients With cMET-dysregulated Advanced Solid TumorsCompletedNCT02520752Phase 1
• INC280 in Healthy Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic FunctionCompletedNCT02474537Phase 1
• A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET AmplificationTerminatedNCT02468661Phase 1
• INC280 Combined With Bevacizumab in Patients With Glioblastoma MultiformeCompletedNCT02386826Phase 1
• Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab TherapyTerminatedNCT02205398Phase 1
• Study of Efficacy and Safety INC280 in Patients With Advanced Hepatocellular CarcinomaWithdrawnNCT01964235Phase 2
• INC280 and Erlotinib Hydrochloride in Treating Patients With Non-small Cell Lung CancerCompletedNCT01911507Phase 1
• A Phase I Study of INC280 in Japanese Patients With Advanced Solid TumorsCompletedNCT01546428Phase 1
• Study of INC280 in Patients With c-MET Dependent Advanced Solid TumorsCompletedNCT01324479Phase 1
• A Dose-escalation Study in Subjects With Advanced MalignanciesCompletedNCT01072266Phase 1

← Capmatinib overview